Wave Life Sciences   Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (2012)

Organization Overview

First Clinical Trial
2017
NCT03225833
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Wave Life Sciences | WAVE Life Sciences | Wave Life Sciences Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

wve-210201 (2 trials)

Drugs in Phase 2 Trials (5)

wve-003 (1 trial)

wve-004 (2 trials)

wve-120101 (2 trials)

wve-120102 (2 trials)

wve-n531 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Huntington Disease (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6